Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 14, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Lung CancerOvarian Cancer
Interventions
DRUG

Diagnostic injection of [123I]I-DARPIN-Ec1

A single intravenous injection of \[123I\]I-DARPIN-Ec1

DIAGNOSTIC_TEST

Whole-body planar scintigraphy with [123I]I-DARPIN-Ec1

Gamma camera-based whole-body planar scintigraphy imaging 2, 4, 6, and 24 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1

DIAGNOSTIC_TEST

Whole-body SPECT with [123I]I-DARPIN-Ec1

Whole-body SPECT at 2, 4, and 6 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1

Trial Locations (1)

Unknown

TomskNRMC, Tomsk

All Listed Sponsors
collaborator

Uppsala University

OTHER

collaborator

The Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry

UNKNOWN

lead

Tomsk National Research Medical Center of the Russian Academy of Sciences

OTHER

NCT06386653 - Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 | Biotech Hunter | Biotech Hunter